Drug intelligence / Profile preview

rotavirus vaccine (live attenuated, oral)

Development stage
Phase 3
Lead developer
Bharat Biotech
Modality
Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration
Oral
01

Overview

ROTAVAC 5D is a monovalent, live attenuated oral vaccine containing the naturally attenuated human-bovine reassortant rotavirus strain 116E (G9P), prepared in Vero cells. It is indicated for the prevention of gastroenteritis caused by rotavirus infection in infants and young children. The vaccine works by stimulating the immune system to produce antibodies against rotavirus without causing disease, thereby providing protection against severe diarrhea due to natural infection. ROTAVAC 5D is administered as a three-dose regimen starting at six weeks of age, with doses given four weeks apart. Developed and manufactured by Bharat Biotech, it features a low-volume liquid formulation that does not require buffer and can be stored at standard refrigeration temperatures (2–8°C), facilitating easier logistics and cold chain management[1][2][4][5].

Brand names
ROTAVAC 5DROTAVAC5DROTAVAC-5D
Other names
rotavirus vaccine (live attenuated, oral)ROTAVAC 5DROTAVAC5DROTAVAC-5D
02

Targets

SA (Sialic acid)

Beyond the preview

Go deeper on rotavirus vaccine (live attenuated, oral).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rotavirus vaccine (live attenuated, oral).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call